What's Hot
View all perspectives
TheDaoIndex KDAO2011
1 year ago
The patients’ voice matters! Watch my interview with @LAlupusLady regarding how she manages #Lupus and her perspective about the disease @rheumnow #ACR23 @uptoTate https://t.co/P9KPJQEkRv
Robert B Chao, MD
1 year ago
All of us need to remind each other to take care of yourself!
Some tips from Dr. Whitney Marvin
- exercise, date night, talking to a friend
- take breaks, mindfulness
- eating away from computer (as I type this on my desk, next to my lunch)
@RheumNow #ACR23 https://t.co/UmmDqXRECN
sheila
1 year ago
Will postpartum BME ⏩axSpA-like structural lesions?
Study by Varkas et al show there was no significant dev't of axSpA-like lesions on MRI in postpartum women 5 yrs after delivery.
Postpartum BME likely sec to transient mech stress-induced SI BME
#ACR23 ABST1892 @RheumNow https://t.co/KJ3DngmkbI
Robert B Chao, MD
1 year ago
Always refreshing to hear from another specialist's point of view
Cardiologist @Bweber04 on CVD and rheumatologic diseases
Increased risk of death, MI and HF exacerbation in our pt population
Increased all cause mortality
@RheumNow #ACR23 https://t.co/yOkPOmxU4N
Robert B Chao, MD
1 year ago
@Bweber04 on recurrent pericarditis especially some seen in our lupus population
IL-1 inhibition with Rilonacept really redefining treatment success and altering the typical treatment algorithm
@RheumNow #ACR23 https://t.co/Ey1DN8eSXT
Eric Dein
1 year ago
Later today at #ACR23 at 4pm
See Ab#2545 on IV secukinumab for AxSpA
Read about it now on @RheumNow:
https://t.co/s9IinpVxgR
Dr. John Cush RheumNow
1 year ago
RheumNow’s expanded coverage of #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow
1 year ago
Watch: Ultrasound for PsA Stratification: Are We There Yet?
Dr. Aurelie Najm reports live from #ACR23
https://t.co/TnDVbKXcd4 https://t.co/RTbjL2wbUj
Mike Putman EBRheum
1 year ago
Interesting counterpoint to a tweet from a few days ago re:black box warning for JAKs
No change in utilization rates post black box... maybe people had already baked this into the cake by then?
@RheumNow #ACR23 Abstr 2142 https://t.co/K9cWbRSWV6
Mike Putman EBRheum
1 year ago
Amazing & thoughtful poster re:protocol violates in TICOSPA trial
51.2% of pts violated T2T protocol at least once... but did not impact primary outcome
Good baseline for future "strategy" style pragmatic trials
@RheumNow #ACR23 #ACRBest Abstr2201 https://t.co/FhctgFNdNP
Md Yuzaiful Md Yusof
1 year ago
#ACR23 Late-Breaking Abstr#L09 In a crowded market, you’ve got to stand out. Phase 2 RCT of LNK01001, a highly selective JAK1-i in China: improvement in ACR 20,50,70 vs PBO at WK12. Those in PBO who didn’t meet ACR20 improved after receiving Tx. Very low infections @RheumNow https://t.co/ZbJFNHOtFT
Eric Dein
1 year ago
A#L09 #ACR23 @RheumNow
New JAK! LNK01001
Chinese pts with mod-severe RA, csDMARD failures
12mg/24mg/PBO: W12: ACR20 60/73/31%, ACR50 40/42/9, ACR70 12/21/2%
Stat signif diff reached at wk 1 for ACR20!
Improved DAS28, HAQ-DI
Wk24 ext: 91% remain in ACR 20
AEs: HLD noted https://t.co/RXOMzxGOTy
Eric Dein
1 year ago
CV Events in AS by Rx
A#L11 @RheumNow #ACR23
43K pts from Korean data
Rates of incident MI or CV:
18.7 per 10,000 py in non-bDMARD pt
8.9 in TNF
12.9 in IL-17
TNFi reduced risk of CVD HR 0.7, not signif for IL-17
Supports idea of TNFi giving a cardioprotective effect?
#ACRBest https://t.co/SvVVDSU23z
Poster Hall